Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.945 AUD | -4.55% | -5.50% | +45.38% |
05-07 | EZZ Life Science Declares Fully Franked Interim Dividend | MT |
04-26 | EZZ Life's Receipts from Customers Up 111% in Fiscal Q3 | MT |
Valuation
Fiscal Period: June | 2021 | 2022 | 2023 |
---|---|---|---|
Capitalization 1 | 18.69 | 13.26 | 21.35 |
Enterprise Value (EV) 1 | 9.915 | 2.895 | 8 |
P/E ratio | 7.44 x | 10 x | 5.88 x |
Yield | 1.01% | 1.45% | 1.96% |
Capitalization / Revenue | 0.84 x | 0.88 x | 0.57 x |
EV / Revenue | 0.44 x | 0.19 x | 0.22 x |
EV / EBITDA | 3.59 x | 1.61 x | 1.71 x |
EV / FCF | -220,439,484 x | 1,800,868 x | 2,379,441 x |
FCF Yield | -0% | 0% | 0% |
Price to Book | 1.85 x | 1.16 x | 1.46 x |
Nbr of stocks (in thousands) | 42,000 | 42,760 | 42,705 |
Reference price 2 | 0.4450 | 0.3100 | 0.5000 |
Announcement Date | 21-09-30 | 22-09-30 | 23-09-28 |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net sales 1 | 11.19 | 17.97 | 22.29 | 15.02 | 37.16 |
EBITDA 1 | 1.181 | 2.179 | 2.765 | 1.799 | 4.678 |
EBIT 1 | 1.177 | 2.156 | 2.748 | 1.784 | 4.659 |
Operating Margin | 10.52% | 12% | 12.33% | 11.88% | 12.54% |
Earnings before Tax (EBT) 1 | 1.177 | 2.15 | 2.737 | 1.78 | 4.901 |
Net income 1 | 0.8238 | 1.586 | 2.031 | 1.312 | 3.63 |
Net margin | 7.36% | 8.83% | 9.11% | 8.74% | 9.77% |
EPS | - | - | 0.0598 | 0.0309 | 0.0850 |
Free Cash Flow | - | 2.554 | -0.045 | 1.608 | 3.362 |
FCF margin | - | 14.21% | -0.2% | 10.7% | 9.05% |
FCF Conversion (EBITDA) | - | 117.19% | - | 89.37% | 71.87% |
FCF Conversion (Net income) | - | 161.01% | - | 122.5% | 92.63% |
Dividend per Share | - | - | 0.004500 | 0.004500 | 0.009800 |
Announcement Date | 21-03-01 | 21-03-01 | 21-09-30 | 22-09-30 | 23-09-28 |
Balance Sheet Analysis
Fiscal Period: June | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | 0.41 | 3.14 | 8.77 | 10.4 | 13.4 |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | 2.55 | -0.04 | 1.61 | 3.36 |
ROE (net income / shareholders' equity) | - | 98.1% | 32.4% | 12.2% | 28% |
ROA (Net income/ Total Assets) | - | 29.6% | 18.8% | 8.48% | 18.3% |
Assets 1 | - | 5.356 | 10.77 | 15.48 | 19.88 |
Book Value Per Share | - | - | 0.2400 | 0.2700 | 0.3400 |
Cash Flow per Share | - | - | 0.2100 | 0.2400 | 0.3200 |
Capex 1 | 0 | 0.09 | 0.01 | 0.01 | 0.1 |
Capex / Sales | 0.02% | 0.5% | 0.03% | 0.04% | 0.27% |
Announcement Date | 21-03-01 | 21-03-01 | 21-09-30 | 22-09-30 | 23-09-28 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+45.38% | 29.29M | |
+38.59% | 727B | |
-7.89% | 347B | |
+15.66% | 319B | |
+0.24% | 274B | |
+13.06% | 238B | |
+7.05% | 204B | |
-5.81% | 203B | |
+4.23% | 161B | |
-1.70% | 160B |
- Stock Market
- Equities
- EZZ Stock
- Financials EZZ Life Science Holdings Limited